| Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and ...

Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...

The best option is to deploy semi-autonomous models where agents recommend actions, but humans validate and approve those actions. As reliability grows over time, organizations will increase their ...

original posters to be presented on cell therapy, patient-reported outcomes, innovative recruitment strategies, and clinical ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug ...

Acknowledging China's innovative biotech environment, UK-headquartered pharmaceutical company AstraZeneca said it is ...

See how Concept Life Sciences accelerated early clinical trials by quickly transferring a client’s process and completing GMP ...

After years of heartbreak, researchers have found an experimental treatment that can slow the progression of Huntington’s ...

Pharmexcil seeks suggestions on regulatory gap in new drug approvals identified by the CDSCO: Shardul Nautiyal, Mumbai Saturday, October 25, 2025, 08:00 Hrs [IST] The Pharmaceutic ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology ...

The UK is facing a pharma exodus. Major pharmaceutical companies have withdrawn about £2 billion in proposed investment from ...

In September 2025, the Russian Federal Medical and Biological Agency announced that a Russian cancer vaccine had passed preclinical trials with promising results. Following this announcement, posts ...